Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Viking Therapeutics ( VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...
Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...
A big rally in defense stocks, deal-fueled gains in banks and a surge in Siemens Energy AG shares were among the main ...
Seeking Alpha on MSN1d
Novo Nordisk seeks to block compounded VictozaNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk (NYSE: NVO) has found phenomenal success in treating patients with obesity and diabetes. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback